ArticleFrontiers in immunology2026
Unrelated cord blood transplantation for pediatric patients with inborn error of immunity and inborn error of metabolism in Vietnam: early single-center experience.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Umbilical cord blood (CB) contains hematopoietic stem and progenitor cells and is an established alternative donor source for hematopoietic stem cell transplantation (HSCT) in both malignant and non-malignant disorders, particularly in children. Patients and methods: We retrospectively studied 12 consecutive pediatric patients with genetically distinct inborn error disorders who underwent single-unit unrelated cord blood transplantation (UCBT) at Vietnam National Children's hospital between October 2020 and February 2026. Outcomes were analyzed descriptively, with emphasis on engraftment, graft failure or rejection, graft-versus-host disease (GVHD), infectious complications, donor chimerism, and immune reconstitution. Result: The median age at transplantation was 19 months (range, 7-42 months), and the median interval from diagnosis to transplantation was 10 months (range, 3-39 months). The study cohort included patients with Wiskott-Aldrich syndrome, very early-onset inflammatory bowel disease caused by an IL10R mutation, severe combined immunodeficiency, major histocompatibility complex class II deficiency, and mucopolysaccharidosis type II. With a median follow-up of 26 months, neutrophil engraftment occurred in nine patients (75%). The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 41.6%, and no patient developed chronic GVHD. Five patients discontinued immunosuppressive therapy. One patient died due to multiorgan failure within the first month after UCBT. Two patients underwent successful haploidentical transplantation because of graft failure, and one patient developed graft rejection after initial engraftment. No additional deaths occurred during follow-up, resulting in an overall survival rate of 91.1% (11/12), whereas the UCBT success rate was 66.7%. The small sample size and relatively short follow-up for some patients restrict the strength of the study. Conclusion: UCBT was feasible for children who required stem cell transplantation but lacked a suitable donor, providing sustained donor engraftment and immune recovery in most long-term survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.